SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Dr. Adam Weiner answers common questions about the costs of androgen deprivation therapy (ADT) for advanced prostate cancer and how to find help paying for it.

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Metformin failed to prevent metabolic syndrome in men on hormonal therapy for prostate cancer but did improve risk factors associated with the syndrome, an abbreviated randomized trial showed.The ...

Find out how ADT + ARPI outperforms ADT alone in mHSPC, boosting survival and treatment persistence. Read more on real-world outcomes.

Real-world outcomes in metastatic prostate cancer patients with ctDNA-detected SPOP mutations. a Sensitivity analysis of all ADT modalities. b Adjusted analysis of current ADT modalities. c Adjusted ...

In a significant policy reversal, the National Institute for Health and Care Excellence (NICE) has recommended abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, ...

Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...

In North American studies, heart failure risk appeared to be lower among patients receiving ADT than it was for the overall analysis, whereas the risk with ADT across Asian studies was higher. The use ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...